Description
Global Next-Generation Breast Cancer Diagnostic and Screening Market: Industry Overview
The global next-generation breast cancer diagnostic and screening market was valued at $3,137.4 million in 2022 and is anticipated to reach $9,880.1 million by 2032, witnessing a CAGR of 12.57% during the forecast period 2023-2032.
The growth in the global next-generation breast cancer diagnostic and screening market is expected to be driven by the increase in the prevalence of breast cancer cases globally, rising awareness regarding early diagnosis of breast cancer, growing focus on breast cancer biomarkers for effective screening, prognosis, and personalized treatment, and increasing partnerships and collaborations amongst market players.
Market Lifecycle Stage
The next-generation breast cancer diagnostic and screening market is in the developing phase. Technological advancements in the development of next-generation breast cancer diagnostics and the growing scope for molecular breast cancer diagnosis techniques in emerging countries can be some of the major opportunities in the global next-generation breast cancer diagnostic and screening market. Furthermore, some of the key trends going on in the market are the implementation of liquid biopsy for breast cancer diagnosis and the complete automation of next-generation techniques.
Impact of COVID-19
COVID-19 had a significant impact on the global next-generation breast cancer diagnostic and screening market. There was a significant shift observed toward research activities for treating and diagnosing COVID-19, which resulted in a halt in research activities for next-generation breast cancer diagnostic and screening. Moreover, the market players witnessed a loss in 2020 due to COVID-19 restrictions and prevention actions such as a reduction in supply chain and sales.
However, since the situations are now almost back to normal, the next-generation breast cancer diagnostic and screening market is expected to overcome all the Impact of COVID-19 during the forecast period 2023-2032.
Market Segmentation:
Segmentation 1: by Technology
• Real-Time PCR
• Immunohistochemistry (IHC)
• Next-Generation Sequencing (NGS)
• Fluorescence In-Situ Hybridization (FISH)
• Others
Based on technology, the global next-generation breast cancer diagnostic and screening market is expected to be dominated by the immunohistochemistry (IHC) segment.
Segmentation 2: by Biomarker
• BRCA1/2
• ER/PR Receptors
• HER-2
• Others
Based on biomarker, the global next-generation breast cancer diagnostic and screening market is dominated by the BRCA1/2 segment.
Segmentation 3: by Cancer Sub-Type
• Luminal A
• Luminal B
• Triple Negative/Basal Like
• Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched
Based on cancer sub-type, the global next-generation breast cancer diagnostic and screening market is dominated by the luminal A segment.
Segmentation 4: by Offering
• Products
• Services
Based on offering, the global next-generation breast cancer diagnostic and screening market is dominated by the services segment.
Segmentation 5: by End User
• Hospitals and Clinics
• Diagnostic Centers and Reference Labs
• Academic and Research Institutes
Based on end user, the global next-generation breast cancer diagnostic and screening market is dominated by the hospitals and clinics segment.
Segmentation 6: by Region
• North America – U.S., Canada
• Europe – Germany, France, U.K., Italy, Spain, and Rest-of-Europe
• Asia-Pacific – Japan, China, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World
Based on region, the global next-generation breast cancer diagnostic and screening market is dominated by North America.
Recent Developments in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
• In April 2023, Syantra Inc., a Canada-based company, received CE mark approval for its Syantra DX breast cancer test.
• In March 2023, NeoGenomics, Inc. launched its RaDaR assay, which is a liquid biopsy test for minimal residual disease (MRD).
• In February 2023, HALO Diagnostics launched its new HALO pathway for early breast cancer detection.
• In January 2023, Agilent Technologies, Inc. acquired Avida Biomed, a company that develops high-performance NGS target enrichment workflows for cancer research.
• In October 2022, Lucence Diagnostics Pte Ltd entered into a distribution partnership with Omnigen, under which Omnigen would distribute Lucence Diagnostics Pte Ltd’s LiquidHALLMARK assay in Turkey.
• In March 2022, Myriad Genetics, Inc. received the U.S. FDA approval for its BRACanalysis CDx for being used as a companion diagnostic test and for the identification of breast cancer patients who may benefit from Lynparza in early breast cancer stages.
• In February 2022, Laboratory Corporation of America Holdings acquired Personal Genome Diagnostics Inc., a company that deals in cancer genomics and provides an assortment of comprehensive liquid biopsy and tissue-based products.
• In January 2022, Agendia Inc. entered into a partnership with Illumina Inc. to expand genomic testing for breast cancer care.
• In December 2021, Exai Bio, Inc. raised funding of $67.5 million as a part of its Series A funding round. The funding was in order to bring advancement in the next-generation RNA-based liquid biopsy platform of the company, which is indicated for early detection of cancer.
• In June 2021, Veracyte, Inc. acquired HalioDx for an amount of $318 million to expand its portfolio in cancer in-vitro diagnostics.
• In May 2021, Hologic, Inc. acquired Biotheranostics, Inc., a company that provides molecular diagnostic tests for breast and metastatic cancers.
• In November 2020, Agilent Technologies, Inc. received U.S. FDA approval for its PD-L1 IHC 22C3 pharmDx for triple-negative breast cancer.
Demand – Drivers and Limitations
Following are the drivers for the global next-generation breast cancer diagnostic and screening market:
• Increasing Prevalence of Breast Cancer Globally
• Increased Awareness Regarding Early Diagnosis of Breast Cancer
• Growing Focus on Breast Cancer Biomarkers for Effective Screening, Prognosis, and Personalized Treatment
• Increasing Partnerships and Collaborations amongst Market Players
The market is expected to face some limitations as well due to the following restraints:
• High Cost of Tests and Requirement of High Capital Investment for Testing Set-Up
• Occurrence of False Positive and False Negative Results
How can this report add value to an organization?
Product/Innovation Strategy: The technology segment helps the reader understand the different types of technologies being used in next-generation breast cancer diagnosis and screening. Moreover, the study provides the reader with a detailed understanding of the next-generation breast cancer diagnostic and screening market based on biomarkers (BRCA1/2, ER/PR receptors, HER-2, and others), cancer sub-type (luminal A, luminal B, triple negative/basal-like, and HER-2 enriched), and offerings (products and services).
Growth/Marketing Strategy: The global next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the global next-generation breast cancer diagnostic and screening market, followed by regulatory and legal activities and mergers and acquisitions.
Competitive Strategy: Key players in the global next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, and market penetration.
Key Companies Profiled
• Abbott Laboratories
• Agendia Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• BGI Genomics Co., Ltd.
• CENTOGENE N.V.
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• Thermo Fisher Scientific Inc.
• Lucence Diagnostics Pte Ltd
• Myriad Genetics, Inc.
• Natera, Inc.
Table of Contents
1 Oncology Molecular Diagnostic Market
1.1 Overview
1.2 Cancer Type
1.3 Technology
1.4 Market Dynamics
1.5 Regulatory-Approved Products
2 Global Next-Generation Breast Cancer Diagnostic and Screening Market
2.1 Global Market Outlook
2.1.1 Product Definition
2.1.2 Definition by Technologies Involved
2.1.2.1 Real-Time Polymerase Chain Reaction (RT-PCR)
2.1.2.2 Fluorescence In-Situ Hybridization (FISH)
2.1.2.3 Next-Generation Sequencing
2.1.2.4 Immunohistochemistry (IHC)
2.1.3 Inclusion and Exclusion
2.1.4 Overview
2.1.4.1 Global Market Size and Growth Potential, $Million, 2022-2032
3 Industry Outlook
3.1 Key Trends
3.1.1 Liquid Biopsy for Breast Cancer Diagnosis
3.1.2 Complete Automation of Next-Generation Techniques
3.2 Regulatory Framework
3.2.1 Regulatory Framework in the U.S.
3.2.1.1 FDA Regulation
3.2.1.2 CMS Regulations (Reimbursement Scenario)
3.2.2 Regulatory Framework in Europe
3.2.3 Regulatory Framework in Asia-Pacific
3.2.3.1 China
3.2.3.2 Japan
3.3 Regulatory-Approved Products
3.4 Clinical Trials
3.5 Breast Cancer Incidence Growth Rates (by Country)
3.6 Advantages and Limitations of Different Techniques
3.7 Pricing
4 Impact of COVID-19 on Global Next-Generation Breast Cancer Diagnostic and Screening Market
4.1 Impact of COVID-19 on Next-Generation Breast Cancer Diagnostic and Screening Overall Market
4.2 Pre-COVID-19 Phase
4.3 During-COVID-19 Phase
4.4 Post-COVID-19 Phase
5 Business Dynamics
5.1 Impact Analysis
5.2 Business Drivers
5.2.1 Increasing Prevalence of Breast Cancer Globally
5.2.2 Increased Awareness Regarding Early Diagnosis of Breast Cancer
5.2.3 Growing Focus on Breast Cancer Biomarkers for Effective Screening, Prognosis, and Personalized Treatment
5.2.4 Increasing Partnerships and Collaborations amongst Market Players
5.3 Business Restraints
5.3.1 High Cost of Tests and Requirement of High Capital Investment for Testing Set-Up
5.3.2 Occurrence of False Positive and False Negative Results
5.4 Business Opportunities
5.4.1 Technological Advancements in the Development of Next-Generation Breast Cancer Diagnostics
5.4.2 Growing Scope for Molecular Breast Cancer Diagnosis Techniques in Emerging Countries
6 Competitive Landscape
6.1 Overview
6.2 Key Strategies and Developments
6.2.1 Partnerships, Alliances, and Business Expansions
6.2.2 Regulatory and Legal Activities
6.2.3 Mergers and Acquisitions
6.2.4 New Offerings
6.2.5 Funding Activities
6.3 Market Share Analysis (by Company), 2022
6.4 Growth-Share Analysis (By Company), 2022
7 Global Next Generation Breast Cancer Diagnostic and Screening Market, By Technology
7.1 Overview
7.2 Growth-Share Matrix
7.3 Real-Time PCR (RT-PCR)
7.4 Immunohistochemistry (IHC)
7.5 Next-Generation Sequencing
7.6 Fluorescence In-Situ Hybridization (FISH)
7.7 Others
8 Global Next Generation Breast Cancer Diagnostic and Screening Market, by Biomarker
8.1 Overview
8.2 Growth-Share Matrix
8.3 BRCA1/2
8.4 ER/PR Receptors
8.5 Human Epidermal Growth Factor-2 (HER-2)
8.6 Others
9 Global Next Generation Breast Cancer Diagnostic and Screening Market, by Cancer Sub-Type
9.1 Overview
9.2 Growth-Share Matrix
9.3 Luminal A
9.4 Luminal B
9.5 Triple Negative/ Basal-Like
9.6 Human Epidermal Growth Factor-2 (HER-2) Enriched
10 Global Next Generation Breast Cancer Diagnostic and Screening Market, by Offering
10.1 Overview
10.2 Growth-Share Matrix
10.3 Products
10.4 Services
11 Global Next Generation Breast Cancer Diagnostics and Screening Market, by End User
11.1 Overview
11.2 Growth-Share Matrix
11.3 Hospitals and Clinics
11.4 Academic and Research Institutes
11.5 Diagnostic Centers and Reference Labs
12 Regions
12.1 North America
12.1.1 Key Findings
12.1.2 Market Dynamics
12.1.2.1 Impact Analysis
12.1.3 Market Sizing and Forecast
12.1.3.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
12.1.3.1.1 U.S.
12.1.3.1.1.1 Market Dynamics
12.1.3.1.1.2 Market Sizing and Forecast
12.1.3.1.2 Canada
12.1.3.1.2.1 Market Dynamics
12.1.3.1.2.2 Market Sizing and Forecast
12.2 Europe
12.2.1 Key Findings
12.2.2 Market Dynamics
12.2.2.1 Impact Analysis
12.2.3 Market Sizing and Forecast
12.2.3.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
12.2.3.1.1 Germany
12.2.3.1.1.1 Market Dynamics
12.2.3.1.1.2 Market Sizing and Forecast
12.2.3.1.2 France
12.2.3.1.2.1 Market Dynamics
12.2.3.1.2.2 Market Sizing and Forecast
12.2.3.1.3 U.K.
12.2.3.1.3.1 Market Dynamics
12.2.3.1.3.2 Market Sizing and Forecast
12.2.3.1.4 Italy
12.2.3.1.4.1 Market Dynamics
12.2.3.1.4.2 Market Sizing and Forecast
12.2.3.1.5 Spain
12.2.3.1.5.1 Market Dynamics
12.2.3.1.5.2 Market Sizing and Forecast
12.2.3.1.6 Rest-of-Europe
12.2.3.1.6.1 Market Dynamics
12.2.3.1.6.2 Market Sizing and Forecast
12.3 Asia-Pacific
12.3.1 Key Findings
12.3.2 Market Dynamics
12.3.2.1 Impact Analysis
12.3.3 Market Sizing and Forecast
12.3.3.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
12.3.3.1.1 China
12.3.3.1.1.1 Market Dynamics
12.3.3.1.1.2 Market Sizing and Forecast
12.3.3.1.2 Japan
12.3.3.1.2.1 Market Dynamics
12.3.3.1.2.2 Market Sizing and Forecast
12.3.3.1.3 India
12.3.3.1.3.1 Market Dynamics
12.3.3.1.3.2 Market Sizing and Forecast
12.3.3.1.4 Australia
12.3.3.1.4.1 Market Dynamics
12.3.3.1.4.2 Market Sizing and Forecast
12.3.3.1.5 South Korea
12.3.3.1.5.1 Market Dynamics
12.3.3.1.5.2 Market Sizing and Forecast
12.3.3.1.6 Singapore
12.3.3.1.6.1 Market Dynamics
12.3.3.1.6.2 Market Sizing and Forecast
12.3.3.1.7 Rest-of-Asia-Pacific
12.3.3.1.7.1 Market Dynamics
12.3.3.1.7.2 Market Sizing and Forecast
12.4 Latin America
12.4.1 Key Findings
12.4.2 Market Dynamics
12.4.2.1 Impact Analysis
12.4.3 Market Sizing and Forecast
12.4.3.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
12.4.3.1.1 Mexico
12.4.3.1.1.1 Market Dynamics
12.4.3.1.1.2 Market Sizing and Forecast
12.4.3.1.2 Brazil
12.4.3.1.2.1 Market Dynamics
12.4.3.1.2.2 Market Sizing and Forecast
12.4.3.1.3 Rest-of-Latin America
12.4.3.1.3.1 Market Dynamics
12.4.3.1.3.2 Market Sizing and Forecast
12.5 Rest-of-the-World
12.5.1 Key Findings
12.5.2 Market Dynamics
12.5.2.1 Impact Analysis
12.5.3 Market Sizing and Forecast
13 Markets - Competitive Benchmarking
13.1 Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
13.2 Company Profiles
13.2.1 Abbott Laboratories
13.2.1.1 Company Overview
13.2.1.2 Role of Abbott Laboratories in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.1.3 Financials
13.2.1.4 Analyst Perception
13.2.2 Agendia Inc.
13.2.2.1 Company Overview
13.2.2.2 Role of Agendia Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.2.3 Recent Developments
13.2.2.4 Analyst Perception
13.2.3 Agilent Technologies, Inc.
13.2.3.1 Company Overview
13.2.3.2 Role of Agilent Technologies, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.3.3 Financials
13.2.3.4 Recent Developments
13.2.3.5 Analyst Perception
13.2.4 Bio-Rad Laboratories, Inc.
13.2.4.1 Company Overview
13.2.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.4.3 Financials
13.2.4.4 Analyst Perception
13.2.5 BGI Genomics Co., Ltd.
13.2.5.1 Company Overview
13.2.5.2 Role of BGI Genomics Co., Ltd. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.5.3 Financials
13.2.5.4 Recent Developments
13.2.5.5 Analyst Perception
13.2.6 CENTOGENE N.V.
13.2.6.1 Company Overview
13.2.6.2 Role of CENTOGENE N.V. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.6.3 Financials
13.2.6.4 Recent Developments
13.2.6.5 Analyst Perception
13.2.7 Danaher Corporation
13.2.7.1 Company Overview
13.2.7.2 Role of Danaher Corporation in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.7.3 Financials
13.2.7.4 Analyst Perception
13.2.8 Exact Sciences Corporation
13.2.8.1 Company Overview
13.2.8.2 Role of Exact Sciences Corporation in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.8.3 Financials
13.2.8.4 Recent Developments
13.2.8.5 Analyst Perception
13.2.9 F. Hoffmann-La Roche Ltd.
13.2.9.1 Company Overview
13.2.9.2 Role of F. Hoffmann-La Roche Ltd. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.9.3 Financials
13.2.9.4 Recent Developments
13.2.9.5 Analyst Perception
13.2.10 Illumina, Inc.
13.2.10.1 Company Overview
13.2.10.2 Role of Illumina, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.10.3 Financials
13.2.10.4 Recent Developments
13.2.10.5 Analyst Perception
13.2.11 Laboratory Corporation of America Holdings
13.2.11.1 Company Overview
13.2.11.2 Role of Laboratory Corporation of America Holdings in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.11.3 Financials
13.2.11.4 Recent Developments
13.2.11.5 Analyst Perception
13.2.12 Thermo Fisher Scientific Inc.
13.2.12.1 Company Overview
13.2.12.2 Role of Thermo Fisher Scientific Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.12.3 Financials
13.2.12.4 Recent Developments
13.2.12.5 Analyst Perception
13.2.13 Lucence Diagnostics Pte Ltd
13.2.13.1 Company Overview
13.2.13.2 Role of Lucence Diagnostics Pte Ltd in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.13.3 Recent Developments
13.2.13.4 Analyst Perception
13.2.14 Myriad Genetics, Inc.
13.2.14.1 Company Overview
13.2.14.2 Role of Myriad Genetics, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.14.3 Financials
13.2.14.4 Recent Developments
13.2.14.5 Analyst Perception
13.2.15 Natera, Inc.
13.2.15.1 Company Overview
13.2.15.2 Role of Natera, Inc. in the Global Next-Generation Breast Cancer Diagnostic and Screening Market
13.2.15.3 Financials
13.2.15.4 Recent Developments
13.2.15.5 Analyst Perception
List of Figures
Figure 1: Worldwide Breast Cancer Statistics (by Region), 2020
Figure 2: Global Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 3: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Technology), $Million, 2022 and 2032
Figure 4: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Biomarker), $Million, 2022 and 2032
Figure 5: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Sub-Type), $Million, 2022 and 2032
Figure 6: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Offering), $Million, 2022 and 2032
Figure 7: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by End User), $Million, 2022 and 2032
Figure 8: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), $Million, 2022 and 2032
Figure 9: Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
Figure 10: Next-Generation Breast Cancer Diagnostic and Screening Market, Key Development Analysis, January 2019-April 2023
Figure 11: Global Next-Generation Breast Cancer Diagnostic and Screening Market Segmentation
Figure 12: Global Next-Generation Breast Cancer Diagnostic and Screening Market: Research Methodology
Figure 13: Primary Research Methodology
Figure 14: Bottom-Up Approach (Segment-Wise Analysis)
Figure 15: Top-Down Approach (Segment-Wise Analysis)
Figure 16: Oncology Molecular Diagnostic Market, Solid Tumor, $Million, 2022 and 2032
Figure 17: Oncology Molecular Diagnostic Market, Hematological Malignancy, $Million, 2022 and 2032
Figure 18: Oncology Molecular Diagnostic Market, Market Dynamics
Figure 19: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Size and Growth Potential, $Million, 2022-2032
Figure 20: Global Market Size and Growth Potential (by Region), $Million, 2022-2032
Figure 21: FDA Guidelines for CDx Approval
Figure 22: Criteria for CMS Coverage/Reimbursement
Figure 23: Europe In-Vitro Diagnostic Devices Regulation Regulatory Process
Figure 24: Breast Cancer Incidence Growth Rates (by Country), 2020 and 2040
Figure 25: Advantages and Limitations of Different Techniques in the Next-Generation Breast Cancer Diagnostic and Screening Market
Figure 26: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
Figure 27: Estimated Number of Global Incidence and Mortality of Breast Cancer in Females, 2020, 2030, and 2040
Figure 28: Breast-Cancer Death Rates with Early Detection and/or Multimodality Treatment
Figure 29: Share of Key Developments and Strategies, January 2019-April 2023
Figure 30: Partnerships, Alliances, and Business Expansions (by Company), January 2019-April 2023
Figure 31: Regulatory and Legal Activities (by Company), January 2019-April 2023
Figure 32: Mergers and Acquisitions (by Company), January 2019-April 2023
Figure 33: New Offerings (by Company), January 2019-April 2023
Figure 34: Funding Activities (by Company), January 2019-April 2023
Figure 35: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Company Revenue Share Analysis, $Million, 2022
Figure 36: Growth-Share Analysis for Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Company), 2022
Figure 37: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Technology)
Figure 38: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Technology), $Million, 2023-2032
Figure 39: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Growth-Share Matrix (by Technology), 2022-2032
Figure 40: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Real-Time PCR), $Million, 2022-2032
Figure 41: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Immunohistochemistry), $Million, 2022-2032
Figure 42: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Next-Generation Sequencing), $Million, 2022-2032
Figure 43: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Fluorescence In-Situ Hybridization), $Million, 2022-2032
Figure 44: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Others), $Million, 2022-2032
Figure 45: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on Other Techniques
Figure 46: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Biomarker)
Figure 47: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Biomarker), $Million, 2023-2032
Figure 48: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Growth-Share Matrix (by Biomarker), 2022-2032
Figure 49: Global Next-Generation Breast Cancer Diagnostic and Screening Market (BRCA1/2), $Million, 2022-2032
Figure 50: Global Next-Generation Breast Cancer Diagnostic and Screening Market (ER/PR Receptors), $Million, 2022-2032
Figure 51: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Human Epidermal Growth Factor-2), $Million, 2022-2032
Figure 52: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Others), $Million, 2022-2032
Figure 53: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Sub-Type)
Figure 54: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Cancer Sub-Type), $Million, 2023-2032
Figure 55: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Growth-Share Matrix (by Cancer Sub-Type), 2022-2032
Figure 56: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Luminal A), $Million, 2022-2032
Figure 57: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Luminal B), $Million, 2022-2032
Figure 58: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Triple-Negative/Basal-Like), $Million, 2022-2032
Figure 59: Global Next-Generation Breast Cancer Diagnostic and Screening Market (HER-2 Enriched), $Million, 2022-2032
Figure 60: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by Offering)
Figure 61: Global Next-Generation Breast Cancer Diagnostic and Screening Market Opportunity (by Offering), $Million, 2023-2032
Figure 62: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Growth-Share Matrix (by Offering), 2022-2032
Figure 63: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Products), $Million, 2022-2032
Figure 64: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Services), $Million, 2022-2032
Figure 65: Global Next-Generation Breast Cancer Diagnostic and Screening Market (by End User)
Figure 66: Global Next-Generation Breast Cancer Diagnostic and Screening Market Opportunity (by End User), $Million, 2023-2032
Figure 67: Global Next-Generation Breast Cancer Diagnostic and Screening Market, Growth-Share Matrix (by End User), 2022-2032
Figure 68: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Hospitals and Clinics), $Million, 2022-2032
Figure 69: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Academic and Research Institutes), $Million, 2022-2032
Figure 70: Global Next-Generation Breast Cancer Diagnostic and Screening Market (Diagnostic Centers and Reference Labs), $Million, 2022-2032
Figure 71: Global Next-Generation Breast Cancer Diagnostic and Screening Market Share (by Region), 2022-2032
Figure 72: North America Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
Figure 73: North America Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 74: North America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
Figure 75: U.S. Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 76: Canada Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 77: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
Figure 78: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 79: Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
Figure 80: Germany Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 81: France Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 82: U.K. Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 83: Italy Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 84: Spain Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 85: Rest-of-Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 86: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
Figure 87: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 88: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
Figure 89: China Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 90: Japan Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 91: India Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 92: Australia Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 93: South Korea Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 94: Singapore Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 95: Rest-of-Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 96: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
Figure 97: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 98: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
Figure 99: Mexico Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 100: Brazil Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 101: Rest-of-Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 102: Rest-of-the-World Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
Figure 103: Abbott Laboratories: Product Portfolio
Figure 104: Abbott Laboratories: Overall Financials, $Million, 2020-2022
Figure 105: Abbott Laboratories: Net Revenue (by Segment), $Million, 2020-2022
Figure 106: Abbott Laboratories: Net Revenue (by Region), $Million, 2020-2022
Figure 107: Abbott Laboratories: R&D Expenditure, $Million, 2020-2022
Figure 108: Agendia Inc.: Product Portfolio
Figure 109: Agilent Technologies, Inc.: Product Portfolio
Figure 110: Agilent Technologies, Inc.: Overall Financials, $Million, 2020-2022
Figure 111: Agilent Technologies, Inc.: Net Revenue (by Segment), $Million, 2020-2022
Figure 112: Agilent Technologies, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 113: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 114: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 115: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2020-2022
Figure 116: Bio-Rad Laboratories, Inc.: Net Revenue (by Segment), $Million, 2020-2022
Figure 117: Bio-Rad Laboratories, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 118: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 119: BGI Genomics Co., Ltd. Product Portfolio
Figure 120: BGI Genomics Co., Ltd.: Overall Financials, $Million, 2020-2022
Figure 121: CENTOGENE N.V.: Product Portfolio
Figure 122: CENTOGENE N.V.: Overall Financials, $Million, 2019-2021
Figure 123: CENTOGENE N.V.: Net Revenue (by Segment), $Million, 2019-2021
Figure 124: CENTOGENE N.V.: Net Revenue (by Region), $Million, 2019-2021
Figure 125: CENTOGENE N.V.: R&D Expenditure, $Million, 2019-2021
Figure 126: Danaher Corporation: Product Portfolio
Figure 127: Danaher Corporation: Overall Financials, $Million, 2020-2022
Figure 128: Danaher Corporation: Net Revenue (by Segment), $Million, 2022
Figure 129: Danaher Corporation: Net Revenue (by Segment), $Million, 2019 and 2020
Figure 130: Danaher Corporation: Net Revenue (by Region), $Million, 2020-2022
Figure 131: Danaher Corporation: R&D Expenditure, $Million, 2020-2022
Figure 132: Exact Sciences Corporation: Product Portfolio
Figure 133: Exact Sciences Corporation: Overall Financials, $Million, 2020-2022
Figure 134: Exact Sciences Corporation: Net Revenue (by Segment), $Million, 2020-2022
Figure 135: Exact Sciences Corporation: Net Revenue (by Region), $Million, 2020-2022
Figure 136: Exact Sciences Corporation: R&D Expenditure, $Million, 2020-2022
Figure 137: F. Hoffmann-La Roche Ltd.: Product Portfolio
Figure 138: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2020-2022
Figure 139: F. Hoffmann-La Roche Ltd.: Net Revenue (by Segment), $Million, 2020-2022
Figure 140: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2020-2022
Figure 141: Illumina, Inc.: Product Portfolio
Figure 142: Illumina, Inc.: Overall Financials, $Million, 2020-2022
Figure 143: Illumina, Inc.: Net Revenue (by Segment), $Million, 2020-2022
Figure 144: Illumina, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 145: Illumina, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 146: Laboratory Corporation of America Holdings: Product Portfolio
Figure 147: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2020-2022
Figure 148: Laboratory Corporation of America Holdings: Net Revenue (by Segment), $Million, 2020-2022
Figure 149: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 150: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
Figure 151: Thermo Fisher Scientific Inc.: Net Revenue (by Segment), $Million, 2020-2022
Figure 152: Thermo Fisher Scientific Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 153: Lucence Diagnostics Pte Ltd: Product Portfolio
Figure 154: Myriad Genetic, Inc.: Product Portfolio
Figure 155: Myriad Genetic, Inc.: Overall Financials, $Million, 2020-2022
Figure 156: Myriad Genetic, Inc.: Net Revenue (by Segment), $Million, 2021-2022
Figure 157: Myriad Genetic, Inc.: Net Revenue (by Segment), $Million, 2020
Figure 158: Myriad Genetic, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 159: Myriad Genetic, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 160: Natera, Inc.: Product Portfolio
Figure 161: Natera, Inc.: Overall Financials, $Million, 2020-2022
Figure 162: Natera, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 163: Natera, Inc.: R&D Expenditure, $Million, 2020-2022
List of Tables
Table 1: Key Questions Answered in the Report
Table 2: Some of the Regulatory-Approved Oncology Molecular Diagnostic Products/Services for Different Types of Solid Tumors
Table 3: Some of the Regulatory-Approved Next-Generation Breast Cancer Diagnostic and Screening Products/Tests
Table 4: Global Next-Generation Breast Cancer Diagnostic and Screening, Clinical Trials
Table 5: Pricing of Some Products/Services for Next-Generation Breast Cancer Diagnostic and Screening
Table 6: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products Offered Based on Real-Time PCR Technique
Table 7: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on Immunohistochemistry (IHC) Technique
Table 8: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on Next-Generation Sequencing (NGS) Technique
Table 9: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on FISH Technique
Table 10: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on BRCA Biomarker
Table 11: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on ER/PR Receptors Biomarker
Table 12: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on HER-2 Biomarker
Table 13: Some of the Next-Generation Breast Cancer Diagnostic and Screening Products/Services Offered Based on Other Biomarkers
Table 14: North America Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
Table 15: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
Table 16: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
Table 17: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
Table 18: Rest-of-the-World Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
Table 19: Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
Table 20: Agendia Inc.: Key Services and Features
Table 21: BGI Genomics Co. Ltd.: Key Products and Features
Table 22: CENTOGENE N.V.: Key Services and Features
Table 23: Danaher Corporation: Key Products and Features
Table 24: Exact Sciences Corporation: Key Services and Features
Table 25: F. Hoffmann-La Roche Ltd.: Key Products and Features
Table 26: Illumina, Inc.: Key Products and Features
Table 27: Laboratory Corporation of America Holdings: Key Products and Features
Table 28: Thermo Fisher Scientific Inc.: Key Products and Features
Table 29: Lucence Diagnostics Pte Ltd: Key Services and Features
Table 30: Myriad Genetics, Inc.: Key Services and Features
Table 31: Natera, Inc.: Key Services and Features
Companies Mentioned
Abbott Laboratories
Agendia Inc.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
BGI Genomics Co., Ltd.
CENTOGENE N.V.
Danaher Corporation
Exact Sciences Corporation
F. Hoffmann-La Roche Ltd.
Illumina, Inc.
Laboratory Corporation of America Holdings
Thermo Fisher Scientific Inc.
Lucence Diagnostics Pte Ltd
Myriad Genetics, Inc.
Natera, Inc.
Reviews
There are no reviews yet.